)
Sanket Koul is a mass communication graduate with a PG diploma in English Journalism from IIMC Delhi. As a correspondent at Business Standard, he covers the pulse of the social sector, from industry and institutional developments, to the government's latest moves in education, healthcare, pharmaceuticals and medical devices sectors.
Sanket Koul is a mass communication graduate with a PG diploma in English Journalism from IIMC Delhi. As a correspondent at Business Standard, he covers the pulse of the social sector, from industry and institutional developments, to the government's latest moves in education, healthcare, pharmaceuticals and medical devices sectors.
The second of a three-part series reports on how education institutes are addressing the skills shortage
Low saturation rates delaying HFR process: Officials
Bold step, but doctors may be concerned over increased legal scrutiny, say experts
National President IMA R V Asokan says doctors have always taken such clinical decisions in good faith
Company claims samples of Pan-D, Clavam 625 tested were spurious, not manufactured by it
The advisory asks states and UTs to continue undertaking appropriate activities to make communities aware of the disease, its modes of spread, and the need for timely reporting and preventive measures
Company claims sample tested was spurious and not manufactured by it
Move comes after drug regulator had suspended nod granted to firm to manufacture, sell PresVu eye drops
According to the estimates, the coverage of private health insurance also showed an upward trend, rising from 5.8 per cent in 2017-18 to 7.4 per cent in 2021-22
State's own scheme will run alongside central plan, according to sources
Sources indicate Punjab state health agency has not submitted audit reports since 2020-21
The Clade 1b strain has been found in a 38-year old man from Kerala's Malappuram district who had tested positive last week
Max Healthcare is on an expansion spree planning to add 3500 beds in 3 yrs
New TB regimen to reduce duration of regimen for drug resistant TB patients to come early next year
The hospital body PHANA claimed that it took the step due to unresolved payments of approximately Rs 600 crore owed by the state government, pending for the last six months
The company is looking at portfolio expansion and increasing the number of products being added each year
First-in-human trial is a type of clinical trial in which a new drug, procedure or treatment is tested in humans for the first time
Move to help Max establish foothold in North India region
AB-PMJAY provides cashless and paperless benefit cover of Rs 5 lakh per annum per family on a floater basis in empanelled hospitals across India
Allocations may be via supplementary demands for grants